BPTES
BPTES is an allosteric and selective glutaminase inhibitor with an IC50 of 0.16 μM.
Product Specifications
CAS Number
314045-39-1
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Glutaminase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BPTES.html
Purity
98.75
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(NC1=NN=C(CCSCCC2=NN=C(NC(CC3=CC=CC=C3)=O)S2)S1)CC4=CC=CC=C4
Molecular Formula
C24H24N6O2S3
Molecular Weight
524.68
Precautions
H315, H319, H335
References & Citations
[1]Elgogary A, et al. Combination therapy with BPTES nanoparticles and targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A. 2016 Sep 6;113 (36) :E5328-36.|[2]Meghan J. Seltzer, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010 Nov 15; 70 (22) : 8981-8987.|[3]Lee JS, et al. Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC. Biochem Biophys Res Commun. 2016 Aug 26;477 (3) :374-82|[4]Lee JS, et al. Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC. Cell Death Dis. 2016 Dec 8;7 (12) :e2511.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6229025-01 0.1 mL
NR4A2 (Nuclear Receptor Subfamily 4, Group A, Member 2, HZF-3, NOT, NURR1, RNR1, TINUR) (MaxLight 650)
Sign In for Pricing
View Details